US FDA Approves GE Pink PineappleDecember 21, 2016
The U.S. Food and Drug Administration (FDA) completed the evaluation of genetically engineered pink flesh pineapple and concluded that it is as safe and nutritious as its conventional pineapple varieties. The pink pineapple was developed by Del Monte Fresh Produce with lower levels of the enzymes that convert pink pigment lycopene to the yellow pigment beta carotene. The new pineapple variety will be identified as "extra sweet pink flesh pineapple" to distinguish it from Del Monte's "golden extra sweet pineapple".
Read the news article from U.S. FDA.
The Crop Biotech Update is a weekly newsletter of ISAAA, a non-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- Report Tackles Role of Biotech Crops in Soil Conservation
- Women MPs Call for Passing on National Biotech and Biosafety Law
- Study Reveals Plant Response to Heat Stress Fluctuates Between Day and Night
- Argentina Approves Commercial Planting of Syngenta GM Corn
- US FDA Approves GE Pink Pineapple
- Australia's OGTR Authorizes Field Trials of GM Banana
- Research Shows Wheat Yields Could Increase by 20% with New Chemical Technology
- OsMADS1 Represses microRNA172 to Regulate the Elongation of Palea and Lemma Development in Rice
Plant Breeding Innovations
- The Application of CRISPR in Dendrobium Orchids
Beyond Crop Biotech
- Whitefly Genome Reveals Why It is a Formidable Threat to Food Security
- Overexpression of AtWRI1 and Hemoglobin Genes Increase Seed Oil Content in Field Cress
- Plant Genome Editing & Genome Engineering
- Biotech Conversations: Real Farmers from Around the World Talk About Biotech
- New ISAAA Video Presents Potential Benefits from Adopting GM Crops
- Articles on Socio-economic Considerations in Biotech Regulation
Subscribe to CBU: